A 58-year-old man with newly diagnosed atrial fibrillation presents with acute right lower limb swelling and pain. Duplex ultrasound confirms deep vein thrombosis (DVT) of the popliteal vein. He has no contraindications to anticoagulation. What is the most appropriate immediate next step in management?

Explanation

## Management of Acute DVT: Immediate Anticoagulation Strategy ### Clinical Context This patient has confirmed symptomatic DVT and requires immediate anticoagulation to prevent pulmonary embolism and reduce post-thrombotic syndrome risk. The choice of initial anticoagulant and transition pathway is critical. ### Parenteral Anticoagulation Options | Agent | Route | Onset | Monitoring | Transition | |-------|-------|-------|-----------|------------| | **UFH** | IV | Immediate (minutes) | aPTT | Direct to warfarin or DOAC | | **LMWH** | SC | 3–4 hours | Anti-Xa (optional) | Day 5–7 to warfarin or DOAC | | **Fondaparinux** | SC | 2–3 hours | Anti-Xa (optional) | Day 5–7 to warfarin or DOAC | | **Thrombolysis** | IV | Minutes | Clinical response | Reserved for massive PE or iliofemoral DVT with limb threat | ### Why Fondaparinux + DOAC Transition Is Optimal **Key Point:** Fondaparinux is a selective Factor Xa inhibitor with predictable pharmacokinetics, no monitoring required, and once-daily dosing. It is non-inferior to LMWH for DVT treatment [cite:Harrison 21e Ch 111]. **High-Yield:** Current guidelines (ACCP 10th edition, 2023) recommend: 1. Initiate parenteral anticoagulation (UFH, LMWH, or fondaparinux) immediately. 2. Transition to warfarin (INR target 2–3) OR DOAC after 5–7 days of parenteral therapy. 3. DOACs (apixaban, rivaroxaban, dabigatran) are preferred over warfarin in most patients due to predictable kinetics and no monitoring. **Clinical Pearl:** Fondaparinux is weight-based (5–10 mg SC daily depending on body weight) and does not require anti-Xa monitoring in routine practice, making it convenient for outpatient initiation. ### Why NOT Thrombolysis Here **Warning:** Thrombolysis is reserved for: - Massive pulmonary embolism with hemodynamic instability. - Iliofemoral DVT with acute limb ischemia (phlegmasia cerulea dolens). - This patient has uncomplicated popliteal DVT — standard anticoagulation is sufficient. ### Why NOT Observation **Key Point:** Untreated DVT carries a 50% risk of symptomatic PE within 2 weeks. Anticoagulation reduces this to <5%. Observation is contraindicated in confirmed DVT. ### Why NOT UFH + Warfarin Simultaneously **Tip:** While UFH is acceptable for rapid anticoagulation (especially if renal impairment or need for urgent procedures), starting warfarin simultaneously without bridging is outdated. Warfarin causes transient hypercoagulability due to early depletion of protein C; bridging with parenteral anticoagulation for 5–7 days is standard. DOACs avoid this issue entirely.